Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

1(11%)

Results Posted

80%(4 trials)

Phase Distribution

Ph phase_2

56%

Ph phase_3

11%

Ph phase_1

22%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

2(25.0%)

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(5)

Terminated(1)

Other(2)

Detailed Status

Completed5

unknown2

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (25.0%)

Phase 25 (62.5%)

Phase 31 (12.5%)

Trials by Status

active_not_recruiting111%

completed556%

unknown222%

withdrawn111%

Recent Activity

1 active trials

Showing 5 of 9

active_not_recruitingphase_2

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018

completedphase_2

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

NCT04082364

completedphase_3

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711

completedphase_2

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

NCT01828021

completedphase_1

Safety Study of MGAH22 in HER2-positive Carcinomas

NCT01148849

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT04425018Phase 2

MARGetuximab Or Trastuzumab (MARGOT)

Active Not Recruiting

NCT04082364Phase 2

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Completed

NCT02492711Phase 3

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

Completed

NCT01828021Phase 2

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Completed

NCT01148849Phase 1

Safety Study of MGAH22 in HER2-positive Carcinomas

Completed

NCT03133988

Margetuximab Expanded Access Program

Unknown

NCT03219268Phase 1

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Completed

NCT04262804Phase 2

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Unknown

NCT05227131Phase 2

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 9